Efficacy of inhaled iloprost in children with pulmonary hypertension after pediatric cardiac surgery: a case series

• Published in: Cardiothoracic Surgeon 2024-12, Vol.32 (1), p.7-7, Article 7
• Main Authors: Arslanoğlu, Ergin, Bakhshaliyev, Shiraslan, Kara, Kenan Abdurrahman, Yiğit, Fatih, Yeşiltaş, Mehmet Ali, Huseynzade, Shabnam, Özalp, Zeynep Gülben Kük, Karaci, Ali Rıza
• Format: Article
• Language: English
• Subjects: Anesthesia; Blood pressure; Cardiac patients; Cardiac Surgery; Cardiovascular disease; Children; Congenital diseases; Congenital heart disease; Drug dosages; Epoprostenol; Genetic disorders; Health aspects; Heart diseases; Heart surgery; Hemodynamics; Hospitals; Hypothermia; Iloprost; Inhaler iloprost; Intensive care; Medical records; Medical research; Medicine; Medicine & Public Health; Medicine, Experimental; Nebul; Patients; Pediatric cardiac surgery; Pediatric cardiology; Pediatrics; Postoperative period; Pulmonary arteries; Pulmonary hypertension; Thoracic Surgery; Veins & arteries; Ventilators
• ISSN: 2662-2203; 2636-333X; 2662-2203
• DOI: 10.1186/s43057-024-00125-1

Background The postoperative phase of cardiac surgery in pediatric patients with congenital heart disease often involves the management of pulmonary hypertension, which can significantly affect recovery and long-term prognosis. Inhaled iloprost is a potent acute pulmonary vasodilator with a rapid onset of action and has been shown to be effective and safe in patients with pulmonary arterial hypertension, improving clinical parameters by lowering pulmonary artery pressure. In our study, we will share the results of patients with pulmonary hypertension after pediatric cardiac surgery in whom we used inhaled iloprost. Results A total of 9 patients who received inhaled iloprost between 2020 and 2023 were included in the retrospective study. The age of the patients ranged between 10 days and 11 months, with a mean of 207.77 days (6.92 months) ± 105.78 days (3.52 months). Five patients were male (55.55%), and four were female (44.45%). Three of the patients had trisomy 21 (33.3%) genetic mutations. Conclusions The limited number of case series in the literature support the potential of inhaliloprost as an effective and safe therapeutic option for the treatment of pulmonary hypertension in the pediatric population after congenital heart surgery. The findings of this study support the literature and suggest that inhaliloprost is effective. Due to the limited number of patients, further research is needed to determine the safety and efficacy of these drugs, especially to determine the dose, route, and duration of administration in intubated patients.